Phase I Study of ABT-888 and Metronomic Cyclophosphamide in Patients With Refractory Solid Tumors or Lymphoma
|Phase I||Biomarker/Laboratory analysis, Treatment||Completed||18 and over||NCI||NCI-09-C-0048|
09-C-0048, 8275, P8437, NCT00810966
ABT-888 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with cyclophosphamide may kill more cancer cells.
This phase I trial is studying the side effects and best dose of ABT-888 when given together with cyclophosphamide in treating patients with solid tumors or lymphoma that did not respond to previous therapy.
Eligibility criteria include the following:
- At least 18 years old
- No glioma or carcinomatous meningitis
- At least 4 weeks since chemotherapy or radiation therapy
- For more information about the eligibility criteria for this trial, refer to the Health Professional version.
Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Patients will receive ABT-888 by mouth once a day for 1-3 weeks. They will also receive cyclophosphamide by mouth once a day for 2 or 3 weeks. Treatment may repeat every 3 weeks for as long as benefit is shown.
After finishing treatment, patients will be evaluated for 1 month.
For more details about this trial, refer to the Health Professional version of the trial summary.
If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.
Trial Lead Organizations
NCI - Center for Cancer Research
|Shivaani Kummar, MD, Principal investigator|
|Official Title||A Phase I Study of ABT-888 in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas|
|Trial Start Date||2008-12-10|
|Trial Completion Date||2012-03-14|
|Registered in ClinicalTrials.gov||NCT00810966|
|Date Submitted to PDQ||2008-12-05|
|Information Last Verified||2012-03-20|